Unicaja Banco S.A. (0RR7)
London Exchange · UK · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 3.162 |
|---|---|
| 52-week range | 2.272 – 3.748 |
| Return, 1 month / 3 months | −12.2% / −3.9% |
| Return, 1 year / 3 years | +42.7% / +269.5% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 33 |
| Volatility (1 year) | 24.5% |
| Worst drawdown (1 year) | -17.8% |
| Average daily value traded | 3.63M EUR |
| Dividend yield | 4.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Unicaja Banco is a Spanish retail bank based in Málaga. It offers current and savings accounts, mortgages, consumer loans, cards and insurance to households, self-employed people and small and medium-sized businesses. It also provides business banking, treasury and investment products, and private banking services. Its branch network and customer base are concentrated in Spain, particularly in Andalusia and other regions where the group's founding savings banks operated.
Unicaja Banco S.A. trades under the code 0RR7 on the London Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Unicaja Banco S.A. (0RR7) trades on the London Exchange in UK. It last closed at EUR 3.162 on 22 October 2026.
Its price-based Market X-Ray is 71 out of 100 (a strong price profile), ranking 480 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 42.7% and over the last three months it fell 3.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 73 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 7.2% | ||
| From 52-week high | -13.8% | ||
| Momentum | 71 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | -3.9% | ||
| 6-month return | 18.6% | ||
| 12-month return, skipping the last month | 62.5% | ||
| Stability (higher is calmer) | 78 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 24.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -17.8% | ||
| Liquidity | 65 · Fair | Moderate trading activity. | |
| Average daily value traded | 3.63M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 58 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.9% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −1.7% |
|---|---|
| 1 month | −12.2% |
| 3 months | −3.9% |
| 6 months | +18.6% |
| 1 year | +42.7% |
| 3 years | +269.5% |
| 5 years | +356.4% |
Signals
| 50-day / 200-day average | 3.452 / 2.949 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.076 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 22 Sep 2026 | EUR 0.0684 |
| 21 Apr 2026 | EUR 0.0863 |
| 23 Sep 2025 | EUR 0.0535 |
| 22 Apr 2025 | EUR 0.0598 |
| 17 Dec 2024 | EUR 0.0486 |
| 17 Apr 2024 | EUR 0.0403 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.